Genenta Science (NASDAQ:GNTA) Trading Down 3.1% – What’s Next?

Posted by Geri Gentry on Aug 18th, 2026

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Get Free Report)’s share price was down 3.1% on Monday . The stock traded as low as $1.2350 and last traded at $1.26. Approximately 59,577 shares were traded during mid-day trading, an increase of 3% from the average daily volume of 58,073 shares. The stock had previously closed at $1.30.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Genenta Science from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

View Our Latest Analysis on Genenta Science

Genenta Science Stock Performance

The business’s fifty day simple moving average is $1.58 and its 200-day simple moving average is $1.11. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.16 and a quick ratio of 14.16.

Institutional Trading of Genenta Science

Large investors have recently modified their holdings of the business. Eurizon Capital SGR S.p.A. bought a new position in Genenta Science during the 4th quarter valued at approximately $536,000. Ghisallo Capital Management LLC bought a new stake in shares of Genenta Science in the 4th quarter worth approximately $482,000. Weiss Asset Management LP bought a new stake in shares of Genenta Science in the 4th quarter worth approximately $480,000. Norges Bank purchased a new position in shares of Genenta Science during the fourth quarter valued at approximately $337,000. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Genenta Science during the fourth quarter valued at approximately $328,000. 15.13% of the stock is owned by institutional investors.

Genenta Science Company Profile

(Get Free Report)

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.